Immune imprinting—sometimes referenced as original antigenic sin—occurs when early-life exposure to influenza biases later responses toward epitopes present in the priming strain. The authors reported that such imprinting can durably shape humoral repertoires, constraining the recruitment of naïve B cells and narrowing responses to drifted or shifted viruses. Influenza vaccines are still mostly delivered intramuscularly. Yet vaccine effectiveness varies by season, age group, and exposure history, and the review asks: how might the vaccine delivery route alter the expression of this ingrained bias? The paper clarifies that direct proof that changing route reprograms established imprinting is essentially absent in the literature; instead, most studies document route-dependent shifts in the types and anatomical distribution of antibodies rather than wholesale reordering of epitope hierarchy.
Early antigen encounters leave molecular marks. The study team described mechanisms where initial B cell and T cell priming bias future clonal selection—memory B cells with specificity for priming epitopes expand preferentially upon re-exposure, outcompeting rare naïve clones. Germinal center dynamics, affinity maturation, and epitope immunodominance together maintain these preferences. Antigen presentation during the priming event establishes patterns of follicular helper T cell support and B cell clonal fitness that are difficult to overturn. The review emphasized that these are mechanistic drivers; it did not provide experimental dosing regimens or quantitative measures because the source did not report them.
Different delivery routes recruit distinct antigen-presenting cell networks and engage separate lymphoid structures. Intramuscular delivery primarily accesses systemic antigen-presenting cells and draining lymph nodes, while mucosal routes (for example intranasal) engage mucosa-associated lymphoid tissues and local dendritic cell subsets. The authors noted available data show route-specific consequences: changes in antibody isotype patterns, altered tissue localization of antibodies, and compartmentalized mucosal versus systemic titers. The review pointed out that such shifts could affect protection at the site of infection even when overall serum neutralization profiles appear similar. The literature cited does not provide conclusive evidence that route alone can change established epitope dominance in previously primed hosts; rather, route appears to modulate where and what kind of antibodies are produced.
The authors framed antigen design and adjuvants as integral variables that interact with delivery route. Conserved-antigen strategies and next-generation platforms aim to target subdominant epitopes or conserved regions of hemagglutinin and other proteins. Adjuvants change innate activation, cytokine milieus, and antigen presentation—factors that influence clonal recruitment and germinal center outcomes. When combined with a route that favors mucosal immunity, for instance, the design space may tilt responses toward different B cell repertoires than intramuscular vaccination alone. The review did not claim that specific adjuvant-route combinations definitively reprogram imprinting; it proposed this integrated approach as a tractable hypothesis for testing in controlled studies.
The review identified several concrete gaps in experimental and clinical work. Investigators reported that experimental models too often omit detailed immune history; prior exposures profoundly shape outcomes yet are rarely incorporated into study design. Authors noted an inadequate routine use of epitope-resolved assays and mucosal readouts, which limits the ability to detect subtle rebalancing of immunodominance. The paper also highlighted the lack of clinical trials with endpoints specifically designed to measure imprinting-related changes—epitope-level shifts, recruitment of naïve clones, or mucosal B cell responses are seldom primary outcomes. Finally, the authors recommended targeted experiments that combine conserved antigens, adjuvants, and alternative delivery routes while explicitly modeling immune history. These studies could answer whether imprinting expression can be broadened or rebalanced, a question the current literature leaves open.
Limitations and unanswered questions
The authors declared no competing interests. They emphasized that direct evidence for reprogramming established imprinting by altering delivery route is essentially lacking. The review made it clear that many experimental details—such as precise dosing strategies, subject selection criteria incorporating immune history, or standardized epitope-resolved assays—were not reported in the literature and therefore remain open methodological gaps. Key unanswered clinical questions include whether specific route-adjuvant-antigen combinations can recruit naïve B cells in primed individuals and whether mucosal readouts will better predict protective breadth against drifted strains. These are the targeted next steps the authors set out for the field.